Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $150
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Kyle Rose maintains a 'Buy' rating on DexCom (NASDAQ:DXCM) and raises the price target from $135 to $150.
July 28, 2023 | 1:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity maintains a 'Buy' rating on DexCom and raises the price target from $135 to $150, which could positively impact the stock's price.
The raised price target by Canaccord Genuity indicates a positive outlook for DexCom. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100